Title: Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone
Authors: Morgan, Gareth ×
Palumbo, Antonio
Dhanasiri, Sujith
Lee, Dawn
Weisel, Katja
Facon, Thierry
Delforge, Michel
Oriol, Albert
Zaki, Mohamed
Yu, Xin
Sternas, Lars
Jacques, Christian
Akehurst, Ron
Offner, Fritz
Dimopoulos, Meletios A #
Issue Date: Mar-2015
Publisher: Blackwell Scientific Publications
Series Title: British Journal of Haematology vol:168 issue:6 pages:820-3
Article number: 10.1111/bjh.13227
Abstract: In the phase III MM-003 trial, pomalidomide plus low-dose dexamethasone (POM+LoDEX) improved overall survival (OS) versus high-dose dexamethasone (HiDEX) in 455 patients with relapsed and refractory multiple myeloma (RRMM) after treatment with bortezomib and lenalidomide. Here, a two-stage Weibull method was used to adjust for the crossover of patients in the HiDEX arm to pomalidomide-based therapy. The adjusted difference in median OS between patients in the POM+LoDEX and HiDEX arms was 7·0 months (12·7 vs. 5·7 months, respectively). These findings provide important evidence for understanding the clinical efficacy of pomalidomide on OS benefits seen in RRMM patients.
ISSN: 0007-1048
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Stem Cell Biology and Embryology (+)
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Morgan.pdf Published 169KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science